Northwest Biotherapeutics Reports Encouraging Data on First Patients Who Have Completed Its Phase I/II Clinical Trial of DCVax(R)-L in Metastatic Ovarian Cancer.

(OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) Northwest Biotherapeutics, Inc. ("NWBT") announced encouraging data on clinical responses in the first two case reports of patients who have completed the Company's Phase I/II clinical trial with DCVax(R)-L personalized cancer vaccine for recurrent, metastatic ovarian cancer (see also Cancer Vaccines).

This trial is ongoing, and is treating "no option" patients who have already been treated with most or all major drugs currently available for recurrent, metastatic ovarian cancer (including carboplatin, paclitaxel, docetaxel, abraxane, gemcitabine and topotecan), and whose cancer has still continued to progress. In other recent clinical trials testing various drugs and drug combinations for …